Related Experiment Video

Updated: May 11, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma

Monika Katharina Guenther1, Ulrike Graab, Simone Fulda

  • 1Institute for Experimental Cancer Research in Pediatrics, Goethe-University Frankfurt, Frankfurt, Germany.

Cancer Letters
|May 21, 2013
PubMed

Insights

Targeting both PI3K/Akt/mTOR and Ras/MEK/ERK pathways simultaneously induces synthetic lethality in rhabdomyosarcoma (RMS). This dual inhibition triggers apoptosis, offering a promising new therapeutic strategy for RMS.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Rhabdomyosarcoma (RMS) often shows simultaneous activation of PI3K/Akt/mTOR and Ras/MEK/ERK signaling pathways.
  • These pathways are critical for RMS cell survival and proliferation.

Purpose of the Study:

  • To investigate the efficacy of simultaneously inhibiting the PI3K/Akt/mTOR and Ras/MEK/ERK pathways in RMS.
  • To determine if cotargeting these pathways leads to synergistic suppression of RMS growth.

Main Methods:

  • Utilized PI3K/mTOR inhibitor PI103 and MEK inhibitor UO126 in various RMS cell lines.
  • Performed genetic knockdown of p110α and MEK1/2.
  • Analyzed signaling pathway modulation, apoptosis markers, and mitochondrial function.

Main Results:

  • PI103 and UO126 demonstrated highly synergistic apoptosis induction in RMS cells (combination index <0.1).
  • Cotreatment suppressed both pathways, unlike single agents which caused cross-activation.
  • Observed downregulation of antiapoptotic proteins (XIAP, Bcl-xL, Mcl-1) and modulation of BimEL.

Conclusions:

  • A synthetic lethal interaction exists between PI3K/mTOR and MEK pathway inhibition in RMS.
  • Combined PI3K/mTOR and MEK inhibition effectively induces apoptosis in RMS.
  • This finding supports the development of novel therapeutic strategies targeting these pathways in RMS treatment.
Keywords:
ApoptosisMAPKPI3KRhabdomyosarcoma

More Related Videos

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...